Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747845 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARDHSD17B1NQO2 | |
| SCHEMBL13047955 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARDHSD17B1NQO2 | |
| SCHEMBL15687648 | 0.92 | ESR1 (0.57) | ESR1ESR2PPARDHSD17B1FFAR1 | |
| SCHEMBL3407376 | 0.89 | MTNR1A (0.57) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL3407380 | 0.89 | MTNR1A (0.57) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL3412841 | 0.89 | MTNR1A (0.57) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL820900 | 0.86 | HSD17B1 (0.61) | ESR1ESR2PPARDHSD17B1NQO2 | |
| SCHEMBL30515129 | 0.86 | HSD17B1 (0.61) | ESR1ESR2PPARDHSD17B1NQO2 | |
| SCHEMBL12035621 | 0.86 | HSD17B1 (0.61) | ESR1ESR2PPARDHSD17B1NQO2 | |
| SCHEMBL2464209 | 0.86 | HSD17B1 (0.61) | ESR1ESR2PPARDHSD17B1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-9988379-B2 | GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG CHEM, LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| US-20150291584-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG CHEM, LTD. (KR) | 2015-10-15 | — | — | US | disclosed |
| EP-2917180-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014073904-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2014-05-15 | — | — | WO | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2260017-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291584-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | GPR119, GPR65, GPR55 | ESR1 354/4885ESR2 771/4885PPARD 192/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | ESR1 2100/4885ESR2 1600/4885PPARD 159/4885 |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | ESR1 85/4885ESR2 222/4885PPARD 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.